Table 2.
Comparison of the characteristics of CAZ–AVI- and/or IMI–REL-resistant clinical isolates
| Strains | MLST | Serotypes | String test | MIC (mg/L) range | Cross resistance (n,%)a | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAZ–AVI | IMI–REL | AMP | AZT | LEV | MIN | CIP | GM | AMK | TGC | PB | |||||||||
| ST11 | KL47 | KL64 | KL10 | 4–8 | 16–32 | 64–128 | ≤ 1 | ≥ 4 | |||||||||||
| Total (n = 22) | 22 | 9 | 12 | 1 | 9 | 1 | 16 | 5 | 16 | 6 |
22, 100.0% |
22, 100.0% |
22, 100.0% |
11, 50.0% |
22, 100.0% |
22, 100.0% |
20, 91.0% |
3, 13.7% |
2, 9.1% |
| Only CAZ–AVI-resistant (n = 16) | 16 | 6 | 9 | 1 | 7 | 0 | 12 | 4 | 16 | 0 |
16, 100.0% |
16, 100.0% |
16, 100.0% |
9, 56.3% |
16, 100.0% |
16, 100.0% |
16, 100.0% |
3, 18.8% |
1, 6.3% |
| CAZ–AVI- and IMI–REL-resistant (n = 5) | 5 | 3 | 2 | 0 | 2 | 0 | 4 | 1 | 0 | 4 |
5, 100.0% |
5, 100.0% |
5, 100.0% |
1, 20.0% |
5, 100.0% |
5, 100.0% |
3, 60.0% |
0, 0.0% |
1, 20.0% |
| Only IMI–REL-resistant (n = 1) | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
1, 100.0% |
1, 100.0% |
1, 100.0% |
1, 100% |
1, 100.0% |
1, 100.0% |
1, 100.0% |
0, 0.0% |
0, 0.0% |
The MIC results of tigecycline were determined according to the US Food and Drug Administration standard
aAMP ampicillin, AZT aztreonam, LEV levofloxacin, MIN minocycline, CIP ciprofloxacin, GM gentamycin, AMK amikacin, TGC tigecycline, PB polymyxin B